These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24908088)

  • 21. Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease.
    Katila N; Bhurtel S; Shadfar S; Srivastav S; Neupane S; Ojha U; Jeong GS; Choi DY
    Neuropharmacology; 2017 Oct; 125():396-407. PubMed ID: 28807678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
    Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y; Zhang Y; Wei Z; Li H; Zhou H; Zhang Z; Zhang Z
    J Neurol Sci; 2009 Oct; 285(1-2):172-7. PubMed ID: 19604516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.
    Bousquet M; Gibrat C; Saint-Pierre M; Julien C; Calon F; Cicchetti F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1401-8. PubMed ID: 19632286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.
    Jarras H; Bourque M; Poirier AA; Morissette M; Coulombe K; Di Paolo T; Soulet D
    J Neuroendocrinol; 2020 Jan; 32(1):e12782. PubMed ID: 31430407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
    Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
    Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.
    Collier TJ; Dung Ling Z; Carvey PM; Fletcher-Turner A; Yurek DM; Sladek JR; Kordower JH
    Exp Neurol; 2005 Feb; 191 Suppl 1():S60-7. PubMed ID: 15629762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
    Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
    Alam G; Edler M; Burchfield S; Richardson JR
    Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.
    Churchill MJ; Cantu MA; Kasanga EA; Moore C; Salvatore MF; Meshul CK
    Neuroscience; 2019 Aug; 414():8-27. PubMed ID: 31220543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of BDNF production by MPP
    Zhang S; Chen S; Liu A; Wan J; Tang L; Zheng N; Xiong Y
    Neurosci Lett; 2018 May; 675():133-139. PubMed ID: 29030221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
    Lai A; Sum J; Fan H; McIntosh JM; Quik M
    Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
    Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A
    Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
    Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH
    Herlinger AL; Almeida AR; Presti-Silva SM; Pereira EV; Andrich F; Pires RGW; Martins-Silva C
    Neuromolecular Med; 2018 Mar; 20(1):73-82. PubMed ID: 29332269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
    Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.